Sugi Predict

Sugi Predict / Targets / BRD9

BRD9

Bromodomain-containing protein 9 · Q9H8M2 · BRD9 on Sugi Atlas →

33,056 patent compounds predicted against BRD9, 17,468 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL414567 SCHEMBL414567 0.52 12/20
SCHEMBL1487941 SCHEMBL1487941 0.52 12/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL2987094) 0.53 6/20
SCHEMBL2642056 SCHEMBL2642056 0.53 6/20
SCHEMBL2571045 SCHEMBL2571045 0.46 6/20
SCHEMBL1541501 SCHEMBL1541501 0.42 6/20
SCHEMBL1948671 SCHEMBL1948671 0.57 5/20
SCHEMBL1450538 SCHEMBL1450538 0.55 5/20
SCHEMBL1771879 SCHEMBL1771879 0.55 5/20
SCHEMBL110927 SCHEMBL110927 0.45 5/20
SCHEMBL1155407 SCHEMBL1155407 0.42 5/20
SCHEMBL2118787 SCHEMBL2118787 0.42 5/20
SCHEMBL979278 SCHEMBL979278 0.60 4/20
SCHEMBL422084 SCHEMBL422084 0.57 4/20
SCHEMBL1238373 SCHEMBL1238373 0.55 4/20
SCHEMBL2172818 SCHEMBL2172818 0.55 4/20
SCHEMBL1356214 SCHEMBL1356214 0.53 4/20
SCHEMBL466352 SCHEMBL466352 0.53 4/20
SCHEMBL2544338 SCHEMBL2544338 0.53 4/20
SCHEMBL762351 SCHEMBL762351 0.52 4/20

Clinical trials — most relevant to BRD9 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD PHASE3COMPLETED
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma PHASE1/PHASE2RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
SMARCA4/2 Inhibitor for POU2F3-Positive SCLC PHASE2NOT_YET_RECRUITING
Elderly Patients With Acute Myeloid Leukemia (AML), Maintenance Phase After Complete Remission (CR) PHASE2COMPLETED
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma PHASE2COMPLETED
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer PHASE2COMPLETED
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab PHASE1/PHASE2RECRUITING
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors PHASE1COMPLETED
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer PHASE1SUSPENDED
LBH589 Oral in Combination With Carboplatin and Paclitaxel in Advanced Solid Tumors PHASE1UNKNOWN
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer PHASE1RECRUITING
SB939 in Treating Patients With Locally Advanced or Metastatic Solid Tumors PHASE1COMPLETED
Expanded Access for Bromodomain and Extra-Terminal (BET) Inhibitor nanNO_LONGER_AVAILABLE
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors nanUNKNOWN
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia nanRECRUITING
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia nanCOMPLETED
A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL nanRECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Clinical, Radiological, Histologic and Molecular Features of a Cohort of Melanocytic Tumors of the Central Nervous System nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a BRD9 binder may also engage these)

ProteinNameSimilarity
Q3UQU0 — 1.000 Q3UQU0 →
Q6GLP7 — 0.992 Q6GLP7 →
Q6NVM8 — 0.991 Q6NVM8 →
Q7ZUF2 — 0.991 Q7ZUF2 →
O88665 — 0.991 O88665 →
BRD7 Bromodomain-containing protein 7 0.991 landscape →
Q02225 — 0.990 Q02225 →
Q5R8B0 — 0.990 Q5R8B0 →
Q9ULJ8 — 0.987 Q9ULJ8 →
Q69ZZ6 — 0.986 Q69ZZ6 →
SMARCC2 SWI/SNF complex subunit SMARCC2 0.986 landscape →
E1BTG2 — 0.986 E1BTG2 →
Q60665 — 0.985 Q60665 →
Q5ZKG2 — 0.985 Q5ZKG2 →
Q09YG9 — 0.985 Q09YG9 →
Q32S26 — 0.985 Q32S26 →
O43439 — 0.985 O43439 →
Q8R310 — 0.984 Q8R310 →
BRD2 Bromodomain-containing protein 2 0.984 landscape →
Q09YJ3 — 0.984 Q09YJ3 →
Q2IBF8 — 0.984 Q2IBF8 →
RBM26 RNA-binding protein 26 0.984 landscape →
Q09YK4 — 0.984 Q09YK4 →
P49140 — 0.984 P49140 →
A5D794 — 0.984 A5D794 →
A0M8T5 — 0.984 A0M8T5 →
Q9Z136 — 0.983 Q9Z136 →
Q8IWZ8 — 0.983 Q8IWZ8 →
Q2IBA2 — 0.983 Q2IBA2 →
Q6NZN0 — 0.983 Q6NZN0 →